April 11, 2022
SciRhom Starts CMC Development of its First Drug Candidate for Clinical Development
SciRhom GmbH has nominated the anti-iRhom2 antibody it will advance into clinical development. For this antibody, the company has closed an agreement with a top-tier biopharmaceutical manufacturer for the CMC development.